Concurrent Investment Advisors LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 30.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,834 shares of the medical instruments supplier’s stock after acquiring an additional 4,196 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $3,461,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after acquiring an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC lifted its position in Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares in the last quarter. Belpointe Asset Management LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $650,000. Finally, Assetmark Inc. lifted its position in Becton, Dickinson and Company by 49.5% during the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock worth $42,294,000 after buying an additional 74,795 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
Insider Buying and Selling at Becton, Dickinson and Company
In other news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.40% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
BDX has been the topic of several analyst reports. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Bank of America boosted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research report on Monday, January 5th. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a research report on Friday, April 10th. They set a “neutral” rating and a $167.00 price target on the stock. Barclays initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price target on the stock. Finally, Stifel Nicolaus boosted their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $189.08.
Get Our Latest Stock Report on BDX
Becton, Dickinson and Company Stock Down 1.3%
Becton, Dickinson and Company stock opened at $150.13 on Tuesday. The firm has a market capitalization of $42.75 billion, a PE ratio of 24.49, a P/E/G ratio of 10.82 and a beta of 0.29. The company’s 50-day moving average is $162.67 and its 200-day moving average is $182.74. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 12.56 earnings per share for the current year.
Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
Receive News & Ratings for Becton Dickinson and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
